Mohit Bansal
Stock Analyst at Wells Fargo
(4.24)
# 328
Out of 4,810 analysts
161
Total ratings
59.57%
Success rate
9.46%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $0.65 | +54.34% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $754.35 | +45.82% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $106.50 | +31.46% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $179.10 | +34.00% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $119.26 | +17.39% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $101.75 | +67.08% | 2 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $60 → $62 | $51.34 | +20.76% | 8 | Feb 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Equal-Weight | $460 | $495.83 | -7.23% | 10 | Jan 30, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $62 → $57 | $61.39 | -7.15% | 6 | Jan 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,050 → $900 | $571.06 | +57.60% | 16 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $293.92 | -4.74% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $26.13 | +14.81% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $102.34 | +66.11% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $21.50 | +225.58% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $79.17 | +38.94% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $14.83 | +82.06% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $59.67 | +50.83% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $22.12 | +35.62% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $94.89 | +79.15% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $13.92 | +93.97% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $33.44 | +49.52% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $5.59 | +33,442.04% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $29.06 | +3.23% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.88 | +4,013.82% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $15.56 | +22.11% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.23 | +2,037.67% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.24 | +4,738.71% | 4 | Dec 3, 2019 |
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $0.65
Upside: +54.34%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $754.35
Upside: +45.82%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $106.50
Upside: +31.46%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $179.10
Upside: +34.00%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $119.26
Upside: +17.39%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $101.75
Upside: +67.08%
Bristol-Myers Squibb Company
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $51.34
Upside: +20.76%
Vertex Pharmaceuticals
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $495.83
Upside: -7.23%
Halozyme Therapeutics
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $62 → $57
Current: $61.39
Upside: -7.15%
Regeneron Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $1,050 → $900
Current: $571.06
Upside: +57.60%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $293.92
Upside: -4.74%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $26.13
Upside: +14.81%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $102.34
Upside: +66.11%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $21.50
Upside: +225.58%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $79.17
Upside: +38.94%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $14.83
Upside: +82.06%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $59.67
Upside: +50.83%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $22.12
Upside: +35.62%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $94.89
Upside: +79.15%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $13.92
Upside: +93.97%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $33.44
Upside: +49.52%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $5.59
Upside: +33,442.04%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $29.06
Upside: +3.23%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $0.88
Upside: +4,013.82%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $15.56
Upside: +22.11%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.23
Upside: +2,037.67%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.24
Upside: +4,738.71%